New combo pill for high blood pressure enters first human tests
NCT ID NCT07421375
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new pill called BR1015-A, which combines two common blood pressure medicines (fimasartan and indapamide) into one tablet. The study will involve 58 healthy adult volunteers to see how the body absorbs and processes the drug, and to check for any safety issues. If results are good, this could lead to a simpler, once-daily treatment option for people with high blood pressure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BR1015-A (combination of fimasartan and indapamide)
What this could lead to
If successful, this could lead to a new once-daily pill that combines two blood-pressure-lowering drugs, making treatment simpler and more effective for people with hypertension.
What could go wrong
This is a very early (Phase 1) study in only 58 healthy volunteers, not patients. It is designed to check safety and how the drug moves through the body, not whether it actually works for hypertension. Many early-stage drugs do not make it to market.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESSENTIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••